SCHEMBL16474690

SCHEMBL16474690

COc1ccc(-c2ccc(=O)n(-c3ccc(OC(C)C)cc3)c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
NPBWR1 P48145 1/20 0.43
MAPT P10636 3/20 0.40
PTPN5 P54829 1/20 0.40
RXFP1 Q9HBX9 2/20 0.39
ALDH1A1 P00352 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ESRRA P11474 1/20 0.39
APP P05067 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
ERN1 O75460 1/20 0.39
RAB9A P51151 1/20 0.39
MAOB P27338 2/20 0.38
CYP11B2 P19099 1/20 0.38
MAOA P21397 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474688 0.89 MEN1 (0.47) KMT2AMEN1TP53HPGDALOX12
SCHEMBL10059805 0.89 KMT2A (0.49) KMT2AMEN1TP53HPGDMAPT
SCHEMBL16474670 0.87 HRH3 (0.50) KMT2APTPN5HRH3MAOBCYP11B2
SCHEMBL10059808 0.84 MAPT (0.51) KMT2AMEN1HPGDNPBWR1MAPT
SCHEMBL16474713 0.83 CA2 (0.47) CA12CA1CA2CA9
SCHEMBL10059918 0.82 HRH3 (0.53) KMT2AMEN1TP53HPGDALOX12
SCHEMBL16474686 0.82 MAPT (0.52) KMT2AMEN1TP53HPGDALOX12
SCHEMBL16474689 0.82 HRH3 (0.53) KMT2AMEN1TP53HPGDALOX12
SCHEMBL10079104 0.82 KDM4E (0.53) KMT2AMEN1HPGDMAPTALDH1A1
SCHEMBL16474752 0.80 ROCK2 (0.45) KMT2ACYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
WO-2015153683-A1 ANTI-FIBROTIC PYRIDINONES INTERMUNE, INC. (US) 2015-10-08 WO disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KMT2A 4574/4885MEN1 4562/4885TP53 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.